Table of Contents Author Guidelines Submit a Manuscript
Sarcoma
Volume 2010 (2010), Article ID 174528, 7 pages
http://dx.doi.org/10.1155/2010/174528
Research Article

Therapeutic Antibodies Targeting CSF1 Impede Macrophage Recruitment in a Xenograft Model of Tenosynovial Giant Cell Tumor

1Department of Pathology and Laboratory Medicine, The University of British Columbia, Vancouver, BC, Canada V5Z 1M9
2British Columbia Cancer Agency, Vancouver, BC, Canada V5Z 1L3

Received 1 June 2010; Accepted 28 September 2010

Academic Editor: Irene Andrulis

Copyright © 2010 Hongwei Cheng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. V. Sharma and E. Y. Cheng, “Outcomes after excision of pigmented villonodular synovitis of the knee,” Clinical Orthopaedics and Related Research, vol. 467, no. 11, pp. 2852–2858, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. L. J. Layfield, A. Meloni-Ehrig, K. Liu, R. Shepard, and J. M. Harrelson, “Malignant giant cell tumor of synovium (malignant pigmented villonodular synovitis): a histopathologic and fluorescence in situ hybridization analysis of 2 cases with review of the literature,” Archives of Pathology and Laboratory Medicine, vol. 124, no. 11, pp. 1636–1641, 2000. View at Google Scholar · View at Scopus
  3. R. B. West, B. P. Rubin, M. A. Miller et al., “A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 3, pp. 690–695, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. J. S. Cupp, M. A. Miller, K. D. Montgomery et al., “Translocation and expression of CSF1 in pigmented villonodular synovitis, tenosynovial giant cell tumor, rheumatoid arthritis and other reactive synovitides,” American Journal of Surgical Pathology, vol. 31, no. 6, pp. 970–976, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. J.-Y. Blay, H. El Sayadi, P. Thiesse, J. Garret, and I. Ray-Coquard, “Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT),” Annals of Oncology, vol. 19, no. 4, pp. 821–822, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. K. S. Siveen and G. Kuttan, “Role of macrophages in tumour progression,” Immunology Letters, vol. 123, no. 2, pp. 97–102, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. P. Paulus, E. R. Stanley, R. Schäfer, D. Abraham, and S. Aharinejad, “Colony-stimulating factor-1 antibody reverses chemoresistance in human MCF-7 breast cancer xenografts,” Cancer Research, vol. 66, no. 8, pp. 4349–4356, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Aharinejad, P. Paulus, M. Sioud et al., “Colony-stimulating factor-1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice,” Cancer Research, vol. 64, no. 15, pp. 5378–5384, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. A. L. Dewar, A. C. Cambareri, A. C. W. Zannettino et al., “Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib,” Blood, vol. 105, no. 8, pp. 3127–3132, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. Y. Wang, M. P. Revelo, D. Sudilovsky et al., “Development and characterization of efficient xenograft models for benign and malignant human prostate tissue,” Prostate, vol. 64, no. 2, pp. 149–159, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. J.-C. Cutz, J. Guan, J. Bayani et al., “Establishment in severe combined immunodeficiency mice of subrenal capsule xenografts and transplantable tumor lines from a variety of primary human lung cancers: potential models for studying tumor progression-related changes,” Clinical Cancer Research, vol. 12, no. 13, pp. 4043–4054, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. D. L. Zimmerman, G. Harrowe, L. Cheng et al., “Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis,” European patent number: EP1572106(B1), European Patent Office, Assignee: Novartis Vaccines and Diagnostics, Inc., Belgium, 2010.
  13. B. Efron, “Better bootstrap confidence intervals,” Journal of the American Statistical Association, vol. 82, no. 397, pp. 171–185, 1987. View at Google Scholar
  14. T. Hiraga and H. Nakamura, “Imatinib mesylate suppresses bone metastases of breast cancer by inhibiting osteoclasts through the blockade of c-Fms signals,” International Journal of Cancer, vol. 124, no. 1, pp. 215–222, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. R. Kerkelä, L. Grazette, R. Yacobi et al., “Cardiotoxicity of the cancer therapeutic agent imatinib mesylate,” Nature Medicine, vol. 12, no. 8, pp. 908–916, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. I. Fichtner, J. Rolff, R. Soong et al., “Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers,” Clinical Cancer Research, vol. 14, no. 20, pp. 6456–6468, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. E. Richardsen, R. D. Uglehus, J. Due, C. Busch, and L.-T. R. Busund, “The prognostic impact of M-CSF, CSF-1 receptor, CD68 and CD3 in prostatic carcinoma,” Histopathology, vol. 53, no. 1, pp. 30–38, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. I. Espinosa, A. H. Beck, C.-H. Lee et al., “Coordinate expression of colony-stimulating factor-1 and colony-stimulating factor-1-related proteins is associated with poor prognosis in gynecological and nongynecological leiomyosarcoma,” American Journal of Pathology, vol. 174, no. 6, pp. 2347–2356, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. M. J. Sweet and D. A. Hume, “CSF-1 as a regulator of macrophage activation and immune responses,” Archivum Immunologiae et Therapiae Experimentalis, vol. 51, no. 3, pp. 169–177, 2003. View at Google Scholar · View at Scopus
  20. K. Kawamura, Y. Komohara, K. Takaishi, H. Katabuchi, and M. Takeya, “Detection of M2 macrophages and colony-stimulating factor 1expression in serous and mucinous ovarian epithelial tumors,” Pathology International, vol. 59, no. 5, pp. 300–305, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. R. D. Leek, R. J. Landers, A. L. Harris, and C. E. Lewis, “Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast,” British Journal of Cancer, vol. 79, no. 5-6, pp. 991–995, 1999. View at Publisher · View at Google Scholar · View at Scopus
  22. I. F. Lissbrant, P. Stattin, P. Wikstrom, J. E. Damber, L. Egevad, and A. Bergh, “Tumor associated macrophages in human prostate cancer: relation to clinicopathological variables and survival,” International Journal of Oncology, vol. 17, no. 3, pp. 445–451, 2000. View at Google Scholar · View at Scopus
  23. C.-H. Lee, I. Espinosa, S. Vrijaldenhoven et al., “Prognostic significance of macrophage infiltration in leiomyosarcomas,” Clinical Cancer Research, vol. 14, no. 5, pp. 1423–1430, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. B. Al-Sarireh and O. Eremin, “Tumour-associated macrophages (TAMS): disordered function, immune suppression and progressive tumour growth,” Journal of the Royal College of Surgeons of Edinburgh, vol. 45, no. 1, pp. 1–16, 2000. View at Google Scholar · View at Scopus
  25. N. Brownlow, A. E. Russell, H. Saravanapavan et al., “Comparison of nilotinib and imatinib inhibition of FMS receptor signaling, macrophage production and osteoclastogenesis,” Leukemia, vol. 22, no. 3, pp. 649–652, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. J. R. Taylor, N. Brownlow, J. Domin, and N. J. Dibb, “FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance,” Oncogene, vol. 25, no. 1, pp. 147–151, 2006. View at Publisher · View at Google Scholar · View at Scopus